1-3 of 3
Johann Zimmermann
Close
Sort by
Journal Articles

POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Daniel Magoon, BS, Li Li, PhD, Barbara Romagnoli, PhD, Garry Douglas, PhD, Gerald Tuffin, PharmD/PhD, Johann Zimmermann, PhD, Patrick Brown, MD
Journal: Blood
Blood (2014) 124 (21): 3707.
https://doi.org/10.1182/blood.V124.21.3707.3707
Published: 2014
Journal Articles

CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma

Abdel Kareem Azab, Ilyas Sahin, Feda Azab, Michele Moschetta, Yuji Mishima, Nicholas Burwick, Johann Zimmermann, Barbara Romagnoli, Kalpana Patel, Eric Chevalier, Aldo M. Roccaro, Irene M. Ghobrial
Journal: Blood
Blood (2014) 124 (12): 1905–1914.
https://doi.org/10.1182/blood-2014-02-558742
Published: 2014
Journal Articles

Dissecting the role of CXCR7 in Cell Trafficking of Endothelial-Cells and Endothelial-Progenitor-Cells in Multiple Myeloma,

Abdel Kareem Azab, PhD, BSPharm, Feda Azab, BPharm, Phong Quang, Patricia Maiso, PhD, Hai T Ngo, BS, Johann Zimmermann, Kalpana Patel, Barbara Romagnoli, Antonio Sacco, BS, Yang Liu, PhD, Yong Zhang, PhD, Michaela Reagan, PhD, Aldo M Roccaro, MD, PhD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2011) 118 (21): 3934.
https://doi.org/10.1182/blood.V118.21.3934.3934
Published: 2011